AlanGoldberg picContractor, Conceptual Mindworks Inc.

Alan Goldberg has been working in pharmaceutical and related industries for over 40 years. For most of that time he has led project teams involved with pharmaceutical product development leading to multiple marketing approvals in several therapeutic areas. He has created and led Project Management Organizations in both industry and non-profits. Alan has received advanced degrees in both Chemistry and Business. Alan is currently a Contractor with Conceptual Mindworks Inc. supporting HHS/ U.S. Government.

Ben Katz photo

Managing Director at HSBC Securities
Social Finance Chair

Ben Katz is an international investment banker specializing in capital raising from fixed income investors and enterprise risk management using interest rate and foreign exchange derivatives to manage risk.  From 1996 through 2010 Ben advised UK and Western European financial institutions and insurance companies and subsequently to the same type of US, Canadian and Bermudian companies. 

Stephen NaylorFounder, Chairman and CEO, MaiHealth

Stephen has over 25 years of experience in the Health and Life Sciences in both the academic and private sectors.  In addition, he is also the founder and served as Executive Management /Chairman of numerous other companies in the personalised medicine, diagnostic, companion diagnostic, biomarker and systems biology sectors.  He has published over 250 scientific journal manuscripts, filed over 20 patents and helped raise in excess of $40 million in federal grants (NIH/SBIR) and $40 million in equity investments for the companies he has been associated with over the past decade.  Stephen has degrees from the University of East Anglia (BSc-1st Class Honors-Chemistry), University of Southampton (MSc-Oceanography), University of California (MS-Chemical Sciences) and University of Cambridge (PhD-Analytical Biochemistry /Chemistry) and also was a Postdoctoral Fellow at MIT.  Over the years he has worked at the MRC (UK), Mayo Clinic (US) and the world’s first systems biology company Beyond Genomics, as well as helped found numerous small start up entities, all in the US.

NorbertRiedelexecportrait2009 011President and Chief Executive Officer, Aptinyx

Dr. Riedel is president and CEO of Aptinyx, as well as a member of the company’s board of directors. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, Dr. Riedel was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Industry Organization.

BrianRoden picSenior Partner, GreenField Chemical

Brian has 25 years experience in the development of branded and generic pharmaceutical products.  Prior to GreenField, a pharmaceutical life cycle management consulting firm, he was a senior consultant for Newport Consulting specializing in pharmaceutical life cycle management.  Previously, Brian was with Abbott Laboratories where he was responsible for the technical support groups for active pharmaceutical ingredient (API) manufacture at the former Abbott North Chicago site. He has experience in supply chain management where he was responsible for negotiating ~$75 million in API raw material supply contracts.  

MichaelRosen

Rosen BioScience Strategies

Michael S. Rosen is Senior Vice President, New Business Development for the Science + Technology Group at Forest City Enterprises, a NYSE-traded national real estate development company which develops and builds bioscience parks across the U.S.  Mr. Rosen works with key research universities affiliated with Forest City bioparks, such as Northwestern University in Chicago, Johns Hopkins University in Baltimore and MIT in Boston, and endeavors to bring life science companies from Europe, Asia, Latin America, India, Israel, and Canada into these parks.

AdriannSax photoEntrepreneur in Residence, Fortress Biotech

Adriann is an Entrepreneur in Residence at Fortress Biotech, a public biotech company which finds and forms subsidiary companies around promising drugs and technologies. For more than 25 years, Adriann has been a global biotech and pharmaceutical industry leader managing all stages of drug development, commercialization, strategic deal-making and partnerships. Prior to Fortress Biotech, Adriann was Executive Vice President, Chief Commercial Officer of Kadmon Corporation leading Kadmon’ s commercial organization, Kadmon Pharmaceuticals, from its inception in September 2010.


Before Kadmon, Adriann was Executive Vice President, Business Development and Strategic Planning at King Pharmaceuticals where she led many profitable transactions in addition to creating and implementing King’s Corporate Strategy for Growth in 2005, contributing to the company’s overall success and ultimate sale to Pfizer in 2011.

JamesTyree

Retired Executive Vice President, Abbott

James L. Tyree has a distinguished career in health care spanning more than thirty years. His accomplishments are well recognized as an investor, operating executive, and entrepreneur. During the last fifteen years, he has held numerous executive positions at Abbott including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition, Executive Vice President Global Pharmaceuticals, and President Abbott Biotech Ventures.

Sign up for our eNewsletter today!

 

First Name




Cures Within Reach

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Monday the 25th. Copyright 2018 Cures Within Reach.